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We report a case of synchronous locally advanced bilateral breast cancer with different pathological responses to
neoadjuvant chemotherapy with different biological character. The patient had presented bilateral breast cancer:
the left breast cancer was hormone receptor negative, human epidermal growth factor receptor-2 (HER2) positive,
and classified as T4bN1M0, stage IIIb, while the right was hormone receptor positive, HER2-negative, and classified
as T4bN0M0, stage IIIb. We administered four cycles of anthracycline-based therapy followed by 12 weekly cycles of
taxane with trastuzumab for neoadjuvant chemotherapy. We had achieved a significant left tumor reduction after
each chemotherapy, but not right tumor. Bilateral modified radical mastectomies with axillary lymph-node
dissection were performed. The therapeutic effect in the left was determined as a pathological complete response,
in contrast to the right side. She has no recurrence for more than five years, though she had advanced cancer with
oncologic emergency. This case could be an informative experience to understand the relation of tumor biology
and response to systemic therapy.
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The escalation of targeting therapy in breast cancer is
supported by a research of tumor biology. To ensure
breast cancer patients receive optimal treatment, the
elucidation of biology from variety fields, such as experi-
mental and clinical research, has been advancing around
world. Estrogen receptor (ER), Progesterone receptor
(PgR), and human epidermal growth factor receptor-2
(HER2) are establish as strong predictive factors to in-
duct each molecular targeting therapy, such as endocrine
therapy and anti-HER2 therapy (Iwase 2008) (Hudis
2007). Moreover, these biological markers have also been
investigated to be concerned with the effects of cytotoxic
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in any medium, provided the original work is pThe number of enormous clinical trials have been
designed to explore optimal treatment and to resolve the
relation of tumor biology with systemic therapy, re-
cently, neoadjuvant chemotherapy (NAC) attracts a high
level of interest instead those of metastatic or adjuvant
setting. NAC is considered to be the most practical an
in vivo measure of chemo-sensitivity and could be pro-
cedure to evaluate relation of biology with treatment re-
sponse, meanwhile NAC reduces tumor size and enables
breast cancer patients to select breast conserving surgery
(Mauri et al. 2005).
The clinical research of NAC is mostly based on clin-
ical trials which consist of a variety of patient groups,
and larger patient samples of well annotated are
demanded to exclude each individual host characteris-
tics. In this time, we experienced a valuable treatment
case, which could reveal a correlation between tumor
biology and response to NAC without host characteris-
tic. The patient had presented synchronous locally ad-
vanced bilateral breast cancers with different biologicalan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Appearance of the bilateral breast cancers at pre- and
post-treatment. The right breast cancer was defined HR-positive
and HER2-negative status at pre-treatment (a). After neoadjuvant
chemotherapy, the right breast cancer presented no significant
change (b). The left breast cancer was defined HR-negative and
HER2-positive at pre-treatment (a). After neoadjuvant chemotherapy
with trastuzumab, the left breast cancer revealed significant
reduction (b).
Figure 2 CT findings of the bilateral axillary lymph nodes at
pre- and post-treatment. At the start of treatment, several lymph
nodes in the left axilla were clearly swelling indicating metastasis
(upper). After neoadjuvant chemotherapy those were not
swelling (lower).
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The therapeutic background of each breast cancer were
similar condition except for the tumor characteristics,
therefore, we reported this meaningful or educational
case to understand the relation of tumor biology and
sensitivity of NAC. Furthermore we also discussed the
relation of NAC response with patient’s prognosis be-
cause it is still under controversial.
Case report
A 60-year-old woman presented with locally advanced
bilateral breast masses that she had noticed in her left
breast 14 months earlier and in her right breast 2 months
earlier. The left mass was 70 × 60 mm in diameter with
blood oozing from skin exposed lesion, and the right
mass was 34 × 32 mm in diameter with skin invasion
(Figure 1a). She was seen in the first clinic because of
oncologic emergency with severe anemia (hemoglobin
3.3 mg/ dl), atrial fibrillation and heart failure. The diag-
nosis of breast cancers were made from core needle bi-
opsy, and the items investigated were histological type,
nuclear grade, ER (6 F11, Ventana), PgR (16, Ventana),
and HER2 overexpression (CB11, Ventana). A computed
tomography scan revealed no distant metastasis, al-
though several lymph nodes in the left axilla were clearly
swelling indicating metastasis (Figure 2). MRI showed a
distinctly irregular contrasting mass of 57 × 42 mm inFigure 3 MRI findings of the bilateral breast cancers at pre-
and post-treatment. MRI showed a distinctly round contrasting
mass of 27 × 19 mm in the right breast (upper right) and a distinctly
irregular contrasting mass of 57 × 42 mm in the left breast (upper
left) at pre-treatment. Each mass had clearly skin invasion, by
contrast each had not reached to the chest wall. After the treatment
the left tumor showed a significant tumor reduction (lower left), but
not right tumor (lower right).
Table 1 Tumor characteristics of the bilateral breast
cancer
Right tumor Left tumor
Characteristics Pre-NAC Post-NAC Pre-NAC Post-NAC
Tumor Size 34 mm 25 mm 70 mm 0 mm
ER positivity 80% 90% 0% -
PgR positivity 40% 60% 0% -
HER2 1+ 2+ FISH 1.2 fold 3+ -
Nuclear Grade 2 1 3 -
NAC neoadjuvant chemotherapy, ER estrogen receptor, PgR progesterone
receptor.
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of 27 × 19 mm in the right breast, nevertheless each
mass had not reached to the chest wall (Figure 3). Serum
tumor marker CA15-3 was slightly elevated 37.7 U/ ml
(upper limit of normal 25.0 U/ mL), but not CEA and
N-ST439. She had no family history of breast and ovar-
ian cancer.
The pretreatment diagnosis were synchronous locally
advanced bilateral breast cancers: the left breast cancer
was defined invasive ductal carcinoma, ER-negative, PgR-
negative, and HER2-positive classified as T4bN1M0, stage
IIIb, while the right breast cancer was defined invasive
ductal carcinoma, ER-positive, PgR-positive, and HER2-
negative classified as T4bN0M0, stage IIIb (Table 1).
We administered four cycles of fluorouracil (500 mg/m2),
epirubicin (100 mg/m2) and cyclophosphamide (500 mg/
m2) every three weeks (FEC), followed by concurrent
weekly trastuzumab (4 mg/kg on day 1 and subsequent
infusions at a dose of 2 mg/kg) with 12 weekly cycles of
paclitaxel (80 mg/m2) for neoadjuvant chemotherapy
(wPac + T). Informed consent was obtained from the pa-
tient before treatment.
We had achieved a significant left tumor reduction
after each chemotherapy, but not right tumor (Figure 1b).
Six months after the start of treatment, we rated the left
breast cancer as clinical complete response (cCR) and
the right breast cancer as clinical stable disease (cSD)
evaluated by RECIST (Therasse et al. 2000) (Figure 3).
Bilateral modified radical mastectomies with axillaryFigure 4 Pathological findings of the bilateral breast cancers after tre
cancer cells with no significant changes (right). In contrast, no cancer cellslymph node dissection were performed. The pathological
responses were assessed in surgical specimens of breast
with reference to the standards of the Japanese Breast
Cancer Society (Kurosumi et al. 2008) (Figure 4). In the
left surgical specimen included lymph nodes, no cancer
cells were observed, thus the therapeutic effect was de-
termined as a pathological complete response (pCR). In
contrast, there were residual invasive cancer cells in the
right side with two of 12 lymph node metastasis. As ad-
juvant therapy, she had received trastuzumab mono-
therapy for nine months and simultaneously received
letrozole for five years. She passed away 71 months after
the start of treatment with no recurrence.Discussion
In this report, we experienced the patient who presented
with synchronous locally advanced bilateral breast can-
cers with different tumor biology: the left breast cancer
was hormone receptor (HR)-negative and HER2-positive
, meanwhile the right breast cancer was HR-positive and
HER2-negative status. We had planned NAC targeting
to the left breast cancer which seemed more progressive
disease, thus we administered FEC followed by wPac + T
and as expected, those mass showed different mass re-
duction responses. Importantly, it is recently reported
that the HR and HER2 status, breast cancer subtype, are
involved with the mass reduction effect of NAC and
pathological response. Furthermore, in term of patient’s
prognosis, there is different significance of pCR depend-
ing on breast cancer subtype (Toi et al. 2008).
It is well known that HER2 overexpression has been as-
sociated with benefit from anthracycline-based chemo-
therapy (Gennari et al. 2008) and trastuzumab-containing
chemotherapy, which is a monoclonal antibody targeting
the extracellular domain of the HER2 protein (Hudis
2007). As regarding NAC, recent randomized trials
present that anthracycline and trastuzumab containing
chemotherapy could achieve higher pathological response
rates (Gianni et al. 2010; Buzdar et al. 2007). Moreover,
treatment response, especially pCR, has a possible surro-
gate marker of patients’ prognosis after NAC (Vonatment. In the right surgical specimen, there were residual invasive
were observed in the left surgical specimen (left).
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breast cancer, the patients with pCR has a better prognosis
than those of non-pCR. Supporting this evidence, even in
our locally advanced case, the left tumor resulted in pCR
and she has no recurrence for about six years after the
start of the treatment.
In related to HR status and systemic therapy, accumu-
lating evidence suggests that the effect of conventional
chemotherapy is greater among HR-negative breast can-
cers (Berry et al. 2006). This is particular striking in the
neoadjuvant setting; HR-negative breast cancer is more
likely to achieve a pCR to NAC compared to those with
HR-positive breast cancer (Ring et al. 2004). HR status is
a strong predictive factor of pCR. However, it is really
important that pathological response to NAC might not
have prognostic significance in patients with HR-positive
breast cancer (Von Minckwitz et al. 2012). It must be
noted, no mass reduction doesn’t lead to no treatment
effect, regarding to prevention of recurrence (Peto et al.
2012). Also in our case, the right mass showed little re-
duction with a lot of lymph node metastasis remaining.
However, fortunately, she has no recurrence for five
years after the completion of NAC, though it was more
likely to have a recurrence even such a locally advanced
and multiple lymph node metastasis.
These days it is common view that breast cancer treat-
ment strategy based on the breast cancer subtypes, con-
sidering target therapy to tumor biology as predictive
factor for breast cancer oncologist (Goldhirsch et al.
2011). However, at that time, it was largely unknown the
meanings of pCR after NAC, and the value of surrogate
marker of patients’ prognosis. This bilateral breast can-
cer case showed typical courses in current treatment
strategy through the NAC based on the tumor biology,
and a long time follow up showed the meaning of patho-
logical response to NAC based on tumor subtype, even
in locally advanced case. This could be the informative
experience to understand the relation of treatment re-
sponse and tumor biology and patient’s prognosis for the
various oncology subspecialists.
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